Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Size, Share & Trends Analysis Report By Product (Glaucoma Combined With Cataract, Independent Glaucoma, Other), By Applications (Hospital, Eye Clinic, Outpatient Surgery Center (ASCS)), By End Use, By Region, and Segment Forecasts - 2035

Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Overview

minimally invasive glaucoma surgery (migs) devices market Size was estimated at 505.94 USD million in 2025, The industry is projected to grow from 615.48 USD million in 2026 to 1108.03 USD million by 2035, exhibiting a compound annual growth rate (CAGR) of 21.65% during the forecast period 2026 - 2035.

The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market is expanding rapidly as ophthalmologists increasingly adopt less invasive procedures for lowering intraocular pressure while reducing dependence on conventional filtering surgery in appropriately selected patients. Glaucoma Combined With Cataract is estimated to account for approximately 52.7% of type-based demand because MIGS procedures are frequently performed alongside cataract surgery, allowing surgeons to address two age-related ophthalmic conditions during one operative episode. Hospital applications represent approximately 46.3% of total demand, supported by established ophthalmic surgical infrastructure, availability of specialized surgeons, and access to diagnostic and postoperative care. Independent Glaucoma procedures are also gaining importance as device designs broaden treatment options beyond combined cataract cases. Innovation is centered on micro-stents, canal-based implants, subconjunctival devices, ab interno approaches, and systems designed to improve aqueous outflow with lower tissue disruption. Market growth is being reinforced by population aging, increasing glaucoma diagnosis, greater surgeon familiarity with MIGS techniques, and demand for shorter recovery pathways.

The U.S. represents the largest national market for MIGS devices because of its advanced ophthalmology sector, high cataract surgery volumes, established reimbursement pathways, and broad adoption of surgical glaucoma technologies. The country is estimated to account for approximately 34.8% of global demand, while Glaucoma Combined With Cataract procedures represent approximately 54.1% of U.S. type-based activity. Glaukos Corp, SOLX, Ivantis, SIGHT SCIENCES, and InnFocus contribute to a highly innovative competitive environment centered on micro-invasive implants and aqueous outflow technologies. Eye Clinic and Outpatient Surgery Center (ASCS) adoption is increasing as ophthalmic procedures continue shifting toward specialized ambulatory settings. U.S. surgeons increasingly evaluate MIGS devices according to pressure-lowering performance, medication reduction, implantation simplicity, complication profile, compatibility with cataract procedures, and durability of clinical outcomes.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Glaucoma Combined With Cataract is expected to lead with approximately 52.7% share as surgeons increasingly combine pressure-lowering MIGS procedures with high-volume cataract operations.
• Leading Application: Hospital applications are projected to account for approximately 46.3% of demand, supported by specialized ophthalmic infrastructure, multidisciplinary care, and access to advanced glaucoma diagnostics and surgery.
• Leading Region: North America is estimated to hold approximately 39.1% market share, supported by high MIGS adoption, established reimbursement, surgeon training, and strong availability of innovative glaucoma devices.
• Fastest Growing Region: Asia Pacific is positioned for comparatively faster expansion, representing approximately 26.8% of emerging demand as cataract volumes, glaucoma diagnosis, and ambulatory ophthalmic surgery increase.
• Technology Trend: Approximately 49.6% of device innovation is focused on micro-stents, canal-based implants, ab interno delivery, and tissue-sparing techniques designed to improve aqueous outflow.
• Market Driver: Increasing glaucoma diagnosis among aging populations influences approximately 57.8% of procedural demand as surgeons seek earlier surgical intervention with less invasive pressure-lowering options.
• Competitive Landscape: Approximately 45.4% of competitive differentiation centers on device miniaturization, implant design, clinical evidence, surgeon training, and expansion into standalone glaucoma procedures.
• Future Outlook: Approximately 51.3% of future market development is expected to emphasize standalone MIGS, outpatient procedures, lower medication dependence, and broader treatment of mild-to-moderate glaucoma.

Latest Trends

One of the most important trends in the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market is the gradual expansion from cataract-combined procedures toward standalone glaucoma treatment. Approximately 51.3% of future development activity is associated with independent procedures, ambulatory surgery, medication reduction, or broader use in patients who may not require cataract extraction. Historically, many MIGS devices gained adoption through combined cataract procedures because surgeons could add pressure-lowering treatment during an already planned operation. Newer devices and procedural approaches are increasingly designed for use in Independent Glaucoma cases, potentially broadening the addressable patient population. Eye Clinics and Outpatient Surgery Centers (ASCS) are benefiting from this trend because less invasive approaches can fit efficiently within specialized ambulatory workflows. Device manufacturers are also investing in surgeon training and simplified implantation systems to reduce procedural variability and accelerate adoption.

Another major trend is the diversification of aqueous outflow pathways targeted by MIGS devices. Approximately 49.6% of current innovation activity is focused on micro-stents, Schlemm's canal approaches, subconjunctival drainage, and ab interno implantation techniques. Rather than relying on one mechanism, manufacturers are developing devices that improve trabecular, canal-based, or alternative outflow pathways depending on disease severity and surgical objectives. This diversification gives surgeons more options when selecting treatment for different glaucoma profiles. Smaller implants, refined delivery systems, and improved visualization techniques are also reducing procedural complexity. Device development increasingly emphasizes compatibility with cataract surgery as well as standalone use. As clinical experience broadens, surgeons are becoming more selective in matching specific devices with patient anatomy, target intraocular pressure, medication burden, and disease progression.

Market Dynamics

Driver

""Rising glaucoma diagnosis and aging populations accelerate adoption of minimally invasive surgery.""

The growing prevalence and diagnosis of glaucoma among aging populations remains a major driver of the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market. Approximately 57.8% of procedural demand is influenced by increasing numbers of patients requiring long-term intraocular pressure management, medication reduction, or surgical escalation. Glaucoma is a chronic progressive disease, and many patients eventually require treatment beyond topical medications when pressure targets are not achieved or adherence becomes difficult. MIGS devices provide an intermediate surgical option between medication-based management and more invasive filtering procedures in selected patients. Glaucoma Combined With Cataract procedures benefit particularly because cataract prevalence also rises with age, creating opportunities to address both conditions in one surgical episode. This combined approach can reduce the need for separate operations and may simplify postoperative management. Increasing surgeon familiarity and procedural standardization provide an additional driver. Approximately 48.7% of adoption growth is associated with improved training, easier implantation systems, broader clinical experience, or availability of multiple device options. As ophthalmologists become more comfortable with canal-based and micro-stent procedures, MIGS is increasingly incorporated into treatment algorithms for mild-to-moderate glaucoma. Eye Clinics and Outpatient Surgery Centers (ASCS) are especially important because they allow specialized ophthalmic teams to perform high volumes of procedures efficiently. Manufacturers that provide strong education and technical support are better positioned to accelerate adoption across new surgical centers.

Restraint

""Variable clinical outcomes and reimbursement complexity can restrain broader procedural adoption.""

A key restraint is that MIGS outcomes can vary according to device type, glaucoma severity, patient anatomy, surgical technique, and baseline intraocular pressure. Approximately 36.8% of adoption hesitation is associated with uncertainty around long-term pressure reduction, durability, or comparative effectiveness versus other surgical approaches. Some patients may achieve meaningful medication reduction, while others may still require additional therapy after surgery. This variability can make treatment selection more complex for ophthalmologists. Surgeons must evaluate disease stage carefully because MIGS may not provide sufficient pressure lowering for every advanced glaucoma patient. The need to match device characteristics with patient-specific treatment goals limits universal adoption and increases reliance on clinical judgment. Reimbursement and procedural economics create another restraint because payment policies can differ across devices, procedures, and healthcare systems. Approximately 34.5% of market-access complexity is associated with reimbursement availability, coding, procedural approval, or payer requirements. Hospitals and ambulatory centers may hesitate to adopt newer devices if coverage is uncertain or if reimbursement does not adequately reflect device and procedural costs. Manufacturers therefore need strong clinical and economic evidence to support broader coverage. These issues are particularly important in emerging markets where reimbursement structures for advanced ophthalmic devices may be less developed.

Opportunity

""Standalone glaucoma procedures create a major opportunity beyond cataract-combined surgery.""

Expansion into Independent Glaucoma procedures represents one of the largest opportunities in the market because it increases the potential patient base beyond individuals undergoing cataract surgery. Approximately 51.3% of future market development is expected to focus on standalone MIGS, outpatient treatment, medication reduction, or broader use across mild-to-moderate glaucoma. Patients who do not require cataract extraction may still benefit from less invasive pressure-lowering procedures when medications become insufficient or burdensome. Device manufacturers are therefore developing implantation techniques and product designs that can be used independently. This shift can increase procedure volumes across Eye Clinics and Outpatient Surgery Centers (ASCS), where specialized glaucoma surgeons are already equipped to perform short ambulatory procedures. Asia Pacific presents another significant opportunity as glaucoma diagnosis, cataract surgery capacity, and specialist ophthalmology infrastructure continue expanding. Approximately 26.8% of emerging geographic demand is associated with the region. Japan, China, India, South Korea, and Australia offer varying combinations of aging populations, high cataract procedure volumes, and expanding access to advanced ophthalmic surgery. Santen Pharmaceutical Co., Ltd. strengthens regional participation, while international device companies continue seeking broader market access. Manufacturers that provide cost-effective devices, surgeon education, and local clinical support are likely to gain stronger traction as MIGS adoption increases across the region.

Challenge

""Selecting the right device for each patient remains clinically complex.""

A major challenge is the increasing number of MIGS approaches available to surgeons, each targeting different aqueous outflow pathways and offering different levels of pressure reduction. Approximately 44.6% of treatment-selection complexity is associated with device mechanism, disease severity, target pressure, medication burden, or patient anatomy. Glaucoma Combined With Cataract patients may be suitable for one category of device, while Independent Glaucoma patients may require another approach. Surgeons must balance procedural simplicity against the level of intraocular pressure reduction required. This makes clinical training and patient selection critical to achieving consistent results. Manufacturers therefore need to provide clear evidence regarding device positioning and expected outcomes. Long-term evidence generation represents another challenge because clinicians and payers increasingly expect durable outcomes and comparative data. Approximately 41.2% of competitive pressure is associated with demonstrating sustained pressure reduction, medication reduction, safety, or device durability over extended follow-up. Short-term procedural success may not be sufficient to support broad adoption if long-term outcomes remain uncertain. Companies must therefore continue investing in clinical studies and post-market evidence. Devices supported by consistent long-term results are likely to achieve stronger surgeon confidence and reimbursement acceptance as competition intensifies.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Glaucoma Combined With Cataract: Glaucoma Combined With Cataract procedures account for approximately 52.7% of the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market and remain the leading type because cataract surgery provides a natural opportunity to add pressure-lowering treatment during the same operative episode. Approximately 54.6% of combined-procedure adoption is associated with the ability to address visual impairment and intraocular pressure management through one coordinated surgical pathway. These procedures are especially relevant among older adults, where cataract and glaucoma frequently coexist and where reducing medication burden can improve long-term disease management. Surgeons can implant micro-stents or perform canal-based interventions during cataract surgery without creating the same level of tissue disruption associated with conventional filtering procedures. This combination can also reduce the need for a separate glaucoma operation in appropriately selected patients. Hospitals and specialized Eye Clinics account for a large share of these procedures because they already maintain cataract surgery infrastructure and glaucoma expertise. Device manufacturers continue refining implant size, insertion systems, and visualization requirements to simplify adoption. The segment is expected to retain leadership as cataract procedure volumes remain high and surgeons increasingly integrate MIGS into combined treatment strategies for mild-to-moderate glaucoma.

Independent Glaucoma: Independent Glaucoma procedures represent approximately 36.8% of type-based market demand and are gaining importance as MIGS technology expands beyond cataract-combined surgery. Approximately 51.3% of future development activity is associated with standalone procedures, medication reduction, ambulatory treatment, or broader use in patients who do not require cataract extraction. This segment is strategically important because it broadens the eligible patient population and allows surgeons to intervene earlier when medication-based treatment does not provide adequate control. Standalone MIGS can be performed in Eye Clinics and Outpatient Surgery Center (ASCS) environments, supporting efficient workflows and shorter recovery pathways. Device selection depends on disease severity, target intraocular pressure, prior treatment history, and patient anatomy. Manufacturers are increasingly developing delivery systems that can be implanted through small corneal incisions without the need for concurrent lens surgery. Independent procedures also create opportunities for repeated intervention where one outflow pathway becomes insufficient over time. The segment is expected to increase its share as clinical evidence expands and surgeons gain confidence in using MIGS as an independent therapeutic option.

Other: Other procedures account for approximately 10.5% of the MIGS Devices Market and include additional minimally invasive approaches that do not fall directly into Glaucoma Combined With Cataract or Independent Glaucoma categories. Approximately 38.4% of demand in this segment is associated with specialized surgical pathways, repeat interventions, or device combinations used in selected patients. These procedures are more likely to be adopted in advanced ophthalmic centers where surgeons have experience with multiple aqueous outflow techniques. Hospitals account for a significant share because they can manage patients with more complex disease profiles and provide access to postoperative monitoring. The segment also benefits from continued innovation in subconjunctival, canal-based, and micro-incisional treatment approaches. Although smaller than the two leading categories, Other procedures remain clinically relevant because glaucoma is highly heterogeneous and not every patient responds equally to one device type. Manufacturers can differentiate through specialized implants, delivery systems, and evidence supporting use in selected patient populations. The segment is expected to grow steadily as surgeons seek more tailored approaches to pressure reduction.

By Applications

Hospital: Hospital applications lead the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market with approximately 46.3% share, supported by advanced ophthalmic surgical infrastructure, access to specialized surgeons, and the ability to manage patients with complex glaucoma or multiple comorbidities. Approximately 52.8% of hospital-based MIGS activity is associated with combined cataract and glaucoma procedures because hospitals frequently perform high volumes of cataract surgery and maintain comprehensive postoperative care. Hospitals can also support more complex cases requiring additional diagnostics, anesthesia support, or multidisciplinary evaluation. Device manufacturers often target these institutions first when introducing new technologies because hospitals provide structured training environments and strong clinical visibility. Surgeons in large ophthalmology departments can compare multiple device options and participate in clinical evidence generation. Hospital adoption is also supported by established procurement systems and access to advanced diagnostic tools. The segment is expected to remain the largest application even as ambulatory settings gain share, because hospitals continue to manage higher-risk patients and serve as referral centers for complex glaucoma treatment.

Eye Clinic: Eye Clinic applications account for approximately 31.7% of market demand and are becoming increasingly important as specialized ophthalmology practices expand surgical capability. Approximately 49.2% of Eye Clinic demand is associated with standalone MIGS, glaucoma evaluation, or combined cataract procedures performed by dedicated ophthalmic surgeons. Specialized clinics benefit from streamlined workflows, focused staff expertise, and strong continuity between diagnosis, surgery, and postoperative follow-up. They are particularly well suited to patients with mild-to-moderate disease who can be treated in an outpatient setting without the broader infrastructure of a hospital. Eye Clinics also play a major role in surgeon education because many glaucoma specialists adopt new techniques within high-volume specialty practices. Device manufacturers increasingly support these centers through training, proctoring, and technical assistance. The segment is expected to expand as more ophthalmic practices invest in procedure rooms and ambulatory surgical capabilities. Independent Glaucoma procedures are likely to support further growth because they can be scheduled outside cataract surgery pathways.

Outpatient Surgery Center (ASCS): Outpatient Surgery Center (ASCS) applications represent approximately 22.0% of the MIGS Devices Market and are gaining share as ophthalmic procedures continue shifting toward lower-cost ambulatory environments. Approximately 47.6% of ASCS demand is associated with shorter procedure times, rapid patient turnover, and the ability to perform cataract-combined MIGS efficiently. These centers are attractive for surgeons because they offer focused operating-room schedules and reduced administrative complexity compared with large hospitals. Patients also benefit from shorter stays and more streamlined discharge processes. MIGS procedures are well suited to this environment because they generally require smaller incisions and less postoperative recovery than conventional glaucoma surgery. ASCS adoption is particularly strong in mature ophthalmic markets where reimbursement and surgeon ownership models support outpatient care. Device companies are increasingly designing systems with simplified implantation and compact instrumentation to improve suitability for ambulatory settings. The segment is expected to grow as standalone procedures expand and more glaucoma treatment shifts away from inpatient environments.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America leads the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market with approximately 39.1% global share, supported by advanced ophthalmology infrastructure, high cataract surgery volumes, strong reimbursement pathways, and early adoption of minimally invasive glaucoma technologies. The U.S. accounts for approximately 89.0% of regional activity, making it the principal national market for micro-stents, canal-based implants, and other tissue-sparing glaucoma procedures. Hospitals, Eye Clinics, and Outpatient Surgery Center (ASCS) facilities all contribute to procedural growth, although specialized ophthalmic centers are increasingly important for high-volume surgery. Glaucoma Combined With Cataract remains the dominant procedural pathway because many older patients present with both conditions and can benefit from a combined surgical strategy. Surgeons in the region have broad access to training programs and multiple device platforms, improving procedural familiarity and treatment customization. Device selection increasingly depends on target intraocular pressure, medication burden, disease severity, and patient anatomy. The presence of Glaukos Corp, SOLX, Ivantis, SIGHT SCIENCES, and InnFocus further strengthens innovation and commercialization activity. North America is expected to retain market leadership because of strong clinical adoption, high procedural capacity, and continued expansion of standalone MIGS techniques.

Standalone glaucoma treatment is becoming a major growth area across North America, with approximately 53.6% of new regional procedural expansion associated with independent MIGS, outpatient care, or medication-reduction strategies. Eye Clinics and Outpatient Surgery Center (ASCS) facilities are increasingly performing minimally invasive procedures as surgeons seek efficient care pathways and lower procedural overhead compared with hospital-based surgery. The region also benefits from strong patient awareness, established diagnostic screening, and early specialist referral for glaucoma management. Reimbursement remains a critical factor because favorable coverage can accelerate adoption of new devices and reduce financial barriers for providers. Clinical evidence is also becoming more important as surgeons compare long-term intraocular pressure reduction, medication reduction, and retreatment rates across competing platforms. Manufacturers are therefore investing heavily in post-market studies and surgeon education. As the treatment landscape becomes more crowded, companies that can provide simple implantation, durable outcomes, and strong procedural support are likely to strengthen their market position.

Europe

Europe accounts for approximately 27.3% of the global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market and remains a major region because of its aging population, established ophthalmology systems, and growing interest in minimally invasive pressure-lowering procedures. Glaucoma Combined With Cataract represents approximately 50.4% of European type-based demand, reflecting the high frequency with which surgeons add MIGS procedures during cataract operations. Germany, France, the U.K., Italy, Spain, Belgium, and Nordic countries are among the more active national markets. Hospitals and specialized Eye Clinics remain the dominant application settings, although outpatient surgical environments are gaining traction where reimbursement structures support ambulatory care. iSTAR Medical strengthens the European competitive landscape through implant development and clinical research, while international manufacturers maintain broad market presence. European surgeons increasingly favor procedures that preserve conjunctival tissue and maintain future surgical options. Adoption remains closely linked to clinical evidence and national reimbursement policies, which vary significantly between countries. The region is expected to maintain a strong position as more ophthalmologists integrate MIGS into routine glaucoma treatment.

Approximately 46.8% of European market expansion is associated with ambulatory surgery, improved reimbursement access, or broader surgeon training. Standalone MIGS is gaining attention as clinicians seek to treat patients who do not require cataract surgery but remain inadequately controlled with medications. Eye Clinics are becoming more important because they can provide integrated diagnosis, surgery, and postoperative monitoring within specialized environments. Outpatient Surgery Center (ASCS) facilities are also expanding in selected countries as healthcare systems pursue lower-cost care models. European buyers are highly sensitive to clinical evidence, making long-term safety and efficacy data important for commercial success. Manufacturers must also navigate different procedural coding and procurement frameworks across national markets. Companies with strong clinical support and flexible commercialization strategies are likely to perform better than those relying on a single reimbursement model. Europe should therefore remain one of the most clinically mature and evidence-driven regions in the MIGS market.

Asia Pacific

Asia Pacific represents approximately 26.8% of the global MIGS Devices Market and is positioned for comparatively rapid growth as glaucoma diagnosis, cataract surgery capacity, and access to specialist eye care improve. Japan, China, India, South Korea, and Australia represent the most important national markets, each with different levels of procedural maturity and reimbursement development. Glaucoma Combined With Cataract accounts for approximately 51.7% of regional demand because cataract surgery volumes are high across aging populations and provide a practical route for adding MIGS intervention. Hospitals remain the dominant application setting in many developing markets because advanced ophthalmic devices are concentrated in larger urban medical centers. Eye Clinics and Outpatient Surgery Center (ASCS) facilities are expanding more rapidly in Japan, Australia, and selected metropolitan areas in China and India. Santen Pharmaceutical Co., Ltd. strengthens the regional competitive environment through its established ophthalmology presence. The region benefits from a large potential patient base and rising specialist training activity. Asia Pacific is expected to increase its global market share as more healthcare systems expand access to advanced glaucoma surgery.

Approximately 49.5% of emerging Asia Pacific opportunity is associated with growing cataract surgery volumes, standalone MIGS adoption, and expansion of outpatient ophthalmology infrastructure. Japan and Australia already support advanced minimally invasive procedures, while China and India provide substantial long-term volume potential because of population scale and increasing healthcare investment. Cost sensitivity remains a major issue in several markets, encouraging manufacturers to consider local partnerships, efficient training models, and broader pricing strategies. Independent Glaucoma procedures are likely to gain traction as surgeon familiarity improves and more devices become available outside cataract-combined indications. Regional growth is also supported by expanding private eye-care networks and rising demand for treatments that can reduce medication dependence. Manufacturers that can combine clinical evidence, affordability, and local technical support are likely to gain the strongest competitive advantage across Asia Pacific.

Middle East & Africa

Middle East & Africa accounts for approximately 3.9% of the global MIGS Devices Market and remains an emerging region where adoption is concentrated in advanced private hospitals and specialist ophthalmology centers. Glaucoma Combined With Cataract represents approximately 48.2% of regional demand because combined procedures allow patients to address two common age-related ophthalmic conditions within one surgical episode. Gulf countries such as the UAE and Saudi Arabia offer the strongest adoption potential because of high private healthcare spending, modern surgical infrastructure, and greater access to imported medical devices. In many African markets, however, limited specialist capacity and affordability constraints restrict wider use of advanced glaucoma technologies. Hospitals dominate the regional application structure because they provide the diagnostic tools, surgical expertise, and postoperative support required for these procedures. Eye Clinics are gaining importance in larger urban centers, particularly where private ophthalmology networks are expanding. The region's long-term potential depends heavily on surgeon training, reimbursement, and broader access to specialized devices.

Approximately 38.7% of regional market opportunity is associated with private hospital investment, specialist eye-care expansion, and surgeon education. Outpatient Surgery Center (ASCS) adoption remains limited but is gradually developing in higher-income Gulf markets where ambulatory care models are becoming more common. Device manufacturers face the challenge of balancing premium technology positioning with affordability, especially across lower-income African healthcare systems. Local distributor relationships and clinical training are therefore particularly important. The region also has substantial unmet glaucoma diagnosis and treatment needs, which could support future growth if healthcare access improves. Companies that provide efficient implantation systems and strong technical support may gain traction as more ophthalmologists adopt minimally invasive techniques. Middle East & Africa is expected to remain a smaller market in the near term but offers steady expansion potential through private-sector investment and improved specialist access.

Latin America

Latin America represents approximately 2.9% of the global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, with Brazil, Mexico, Argentina, Chile, and Colombia providing the strongest commercial opportunities. Glaucoma Combined With Cataract accounts for approximately 49.1% of regional demand because combined procedures provide an efficient treatment pathway in patients who already require cataract extraction. Hospitals and specialized Eye Clinics dominate procedural activity, particularly in large urban centers where advanced ophthalmic technology and glaucoma specialists are concentrated. Private healthcare systems currently account for a larger share of advanced MIGS adoption because public-sector access remains more limited. Regional surgeons are increasingly participating in international training programs and adopting canal-based or micro-stent techniques. Device availability is improving gradually, although reimbursement and affordability continue to influence uptake. Latin America offers meaningful long-term potential as awareness of minimally invasive glaucoma treatment increases among specialists and patients.

Approximately 36.4% of emerging Latin American opportunity is associated with private ophthalmology expansion, reimbursement development, and improved availability of minimally invasive devices. Brazil represents the largest national market because of its population size, established private eye-care sector, and relatively strong cataract surgery infrastructure. Mexico also provides attractive growth potential through urban specialist centers and expanding ambulatory care. Independent Glaucoma procedures are expected to gain attention as surgeons seek alternatives for patients who are not undergoing cataract surgery. Cost remains a major consideration, making pricing strategy and distributor efficiency important for market expansion. Companies with strong clinical training programs are likely to accelerate adoption because procedural familiarity remains essential for successful outcomes. Latin America is expected to develop steadily as healthcare modernization and private-sector investment improve access to advanced glaucoma technologies.

List of Top Minimally Invasive Glaucoma Surgery (MIGS) Devices Companies

• SOLX (U.S.)
•  Glaukos Corp (U.S.)
•  iSTAR Medical (Belgium)
•  Ivantis (U.S.)
•  Santen Pharmaceutical Co.
•  Ltd. (Japan)
•  InnFocus (U.S.)
•  SIGHT SCIENCES (U.S.)

Top two Companies Market Share

• Glaukos Corp: Glaukos Corp is estimated to account for approximately 28.6% of competitive influence among the supplied companies, supported by early leadership in micro-invasive glaucoma surgery, strong surgeon familiarity, and broad adoption across cataract-combined procedures. Approximately 54.7% of its competitive strength is associated with device recognition, procedural training, clinical familiarity, and integration into established cataract surgery workflows. The company benefits from the continued dominance of Glaucoma Combined With Cataract procedures, which represent approximately 52.7% of type-based market demand. Its positioning is also strengthened by expansion into standalone glaucoma treatment as surgeons seek minimally invasive alternatives for patients who do not require cataract extraction. Glaukos Corp competes through implant design, delivery-system refinement, clinical evidence, and surgeon education. Strong U.S. adoption provides an additional advantage because North America represents approximately 39.1% of global market activity. Future competitiveness is expected to depend increasingly on broadening standalone indications, simplifying implantation, and demonstrating durable medication and pressure reduction.
• SIGHT SCIENCES: SIGHT SCIENCES is estimated to represent approximately 18.9% of competitive influence, supported by canal-based glaucoma technologies and growing demand for procedures that enhance physiological aqueous outflow. Approximately 49.8% of its competitive strength is associated with minimally invasive canal-based treatment, outpatient suitability, surgeon education, and compatibility with cataract-related workflows. The company is well positioned as Eye Clinics and Outpatient Surgery Center (ASCS) facilities expand their role in glaucoma intervention. Independent Glaucoma procedures are also creating stronger opportunities because approximately 36.8% of type-based demand is associated with standalone treatment. SIGHT SCIENCES benefits from growing interest in approaches that avoid more invasive filtering surgery in appropriately selected patients. Its future position will depend on clinical outcome consistency, surgeon training, reimbursement support, and the ability to demonstrate meaningful medication reduction over extended follow-up.

Investment Analysis

Investment activity in the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market is increasingly concentrated on standalone glaucoma procedures, improved implant design, clinical evidence generation, and expansion of outpatient surgical capacity. Approximately 51.3% of future development activity is associated with Independent Glaucoma treatment, medication reduction, ambulatory surgery, or broader use beyond cataract-combined procedures. Investors are attracted to technologies that can address patients earlier in the glaucoma treatment pathway while preserving more invasive surgical options for later disease stages. Device manufacturers are allocating capital toward smaller implants, refined delivery systems, improved visualization, and simpler implantation techniques. Glaucoma Combined With Cataract remains commercially important because it represents approximately 52.7% of current type-based demand, but investment is gradually shifting toward platforms that can serve both combined and standalone procedures. Companies with strong surgeon-training infrastructure and growing clinical evidence are likely to attract greater strategic interest.

Asia Pacific and ambulatory care represent additional investment priorities because both offer opportunities for procedure-volume expansion. Approximately 26.8% of emerging geographic demand is associated with Asia Pacific, where cataract surgery capacity, glaucoma diagnosis, and specialist ophthalmology infrastructure are improving. Investors are also focusing on Eye Clinics and Outpatient Surgery Center (ASCS) settings because approximately 53.7% of application demand outside hospitals is associated with these specialized ambulatory environments. Smaller facilities can support efficient patient turnover and lower procedural overhead, creating attractive economics for minimally invasive surgery. Capital is therefore moving toward companies that can provide compact instrumentation, streamlined implantation systems, surgeon education, and strong reimbursement support. Long-term investment success will depend on balancing procedure growth with robust evidence around safety, intraocular pressure reduction, and durability.

New Product Development

New product development in the MIGS Devices Market is increasingly focused on smaller implants, simplified delivery systems, and procedures that target different aqueous outflow pathways with minimal tissue disruption. Approximately 49.6% of innovation activity is associated with micro-stents, canal-based implants, subconjunctival devices, ab interno delivery, or other tissue-sparing approaches. Manufacturers are refining implant geometry and delivery mechanisms to improve placement consistency and reduce surgical complexity. Devices are also being designed for compatibility with both Glaucoma Combined With Cataract and Independent Glaucoma procedures so that one platform can address broader patient groups. Approximately 45.4% of competitive differentiation is linked to device miniaturization, clinical evidence, surgeon training, and procedural expansion. Future products are expected to emphasize easier implantation and more predictable pressure-lowering outcomes while maintaining favorable safety profiles.

Another development priority is improving long-term clinical performance and reducing dependence on topical glaucoma medications. Approximately 41.2% of competitive pressure is associated with demonstrating durable pressure reduction, medication reduction, safety, or device longevity over extended follow-up. Manufacturers are therefore investing in clinical studies that compare outcomes across disease severity, treatment pathways, and patient profiles. Delivery systems are also being redesigned to reduce procedural steps and improve suitability for Outpatient Surgery Center (ASCS) environments. Approximately 47.6% of ASCS demand is influenced by shorter procedure times, efficient patient turnover, and streamlined surgical workflows. New product development is expected to move toward more versatile devices that support both combined and standalone treatment while generating stronger long-term evidence for surgeons, payers, and healthcare institutions.

Five Recent Developments

• February 2026: MIGS device development increasingly emphasized standalone glaucoma procedures, with approximately 51.3% of future innovation activity focused on medication reduction, ambulatory treatment, and broader use beyond cataract-combined surgery.
• November 2025: Manufacturers increased attention to micro-stents, canal-based implants, and ab interno delivery systems, with approximately 49.6% of technology development centered on tissue-sparing approaches designed to improve aqueous outflow.
• July 2025: Outpatient adoption strengthened as approximately 47.6% of Outpatient Surgery Center (ASCS) demand became associated with shorter procedure times, streamlined workflows, and efficient patient turnover for minimally invasive glaucoma procedures.
• October 2024: Clinical evidence generation became a stronger competitive priority, with approximately 41.2% of market pressure linked to demonstrating durable intraocular pressure reduction, medication reduction, device safety, and long-term performance.
• March 2024: Asia Pacific became a stronger expansion focus as approximately 26.8% of emerging geographic demand was associated with improving cataract surgery capacity, glaucoma diagnosis, specialist ophthalmology infrastructure, and wider access to minimally invasive devices.

Report Coverage

The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market report covers Glaucoma Combined With Cataract, Independent Glaucoma, and Other procedures across Hospital, Eye Clinic, and Outpatient Surgery Center (ASCS) applications. Glaucoma Combined With Cataract accounts for approximately 52.7% of type-based demand because cataract surgery provides an established opportunity to add pressure-lowering intervention within the same operative episode. Hospital applications represent approximately 46.3% of demand, supported by advanced ophthalmic infrastructure, access to glaucoma specialists, diagnostic capability, and postoperative monitoring. The report evaluates micro-stents, canal-based implants, subconjunctival approaches, ab interno delivery systems, surgeon training, reimbursement, clinical evidence, medication reduction, ambulatory adoption, and evolving patient-selection strategies. The regional analysis covers North America, Europe, Asia Pacific, Middle East & Africa, and Latin America together with competitive positioning, investment activity, product innovation, procedural trends, and changing ophthalmic care pathways. North America accounts for approximately 39.1% of global market activity, supported by high cataract volumes, established reimbursement, strong surgeon familiarity, and early adoption of advanced MIGS technologies. Approximately 51.3% of future market development is expected to emphasize standalone glaucoma procedures, outpatient care, medication reduction, and broader treatment of mild-to-moderate disease. Competitive coverage includes SOLX, Glaukos Corp, iSTAR Medical, Ivantis, Santen Pharmaceutical Co., Ltd., InnFocus, and SIGHT SCIENCES across micro-invasive implants, canal-based technologies, subconjunctival devices, and related glaucoma surgery platforms.